Businesses
Here's a look at documents from U.S. and international businesses
Featured Stories
AACR 2026: Real-World Data Show Targeted Therapy Extends Survival in Aggressive Form of Colorectal Cancer
BUFFALO, New York, April 19 [Category: BizHospital] -- The Roswell Park Comprehensive Cancer Center posted the following news release:
* * *
AACR 2026: Real-World Data Show Targeted Therapy Extends Survival in Aggressive Form of Colorectal Cancer
*
BUFFALO, N.Y. and SAN DIEGO -HER2-positive, metastatic colorectal cancer is an aggressive disease that often shows limited response to standard chemotherapy. A new study from Roswell Park Comprehensive Cancer Center, highlighted today at the 2026 annual meeting of the American Association for Cancer Research (AACR) in San Diego, California, suggests
... Show Full Article
BUFFALO, New York, April 19 [Category: BizHospital] -- The Roswell Park Comprehensive Cancer Center posted the following news release:
* * *
AACR 2026: Real-World Data Show Targeted Therapy Extends Survival in Aggressive Form of Colorectal Cancer
*
BUFFALO, N.Y. and SAN DIEGO -HER2-positive, metastatic colorectal cancer is an aggressive disease that often shows limited response to standard chemotherapy. A new study from Roswell Park Comprehensive Cancer Center, highlighted today at the 2026 annual meeting of the American Association for Cancer Research (AACR) in San Diego, California, suggeststhat patients with HER2-positive metastatic colorectal cancer may live longer when treated with the targeted therapy trastuzumab deruxtecan (T-DXd, brand name Enhertu) compared to standard chemotherapy. The findings provide important evidence that the survival benefits previously seen in clinical trials also hold up in everyday cancer care.
While clinical trials have demonstrated that trastuzumab deruxtecan (T-DXd/Enhertu) can prolong overall survival, until now its effectiveness outside the context of a clinical trial has been unclear. Zunairah Shah, MBBS, co-first author of the study, will share her team's findings in Abstract 1303, "Real-world overall survival with trastuzumab deruxtecan versus standard chemotherapy in HER2-amplified MSS metastatic colorectal cancer," Sunday, April 19, 3:35-3:50 p.m. PDT in room 17, Mezzanine Level of the San Diego Convention Center.
T-DXd, a type of targeted therapy called an antibody-drug conjugate, delivers chemotherapy directly to cancer cells that overexpress the protein HER2, bypassing healthy cells. Past clinical trials evaluated T-DXd in patients who had received two or more prior lines of therapy. However, in other tumor types, antibody-drug conjugates have shown greater benefit when used earlier in the treatment course, as seen in DESTINY-Breast09. Consequently, the team retrospectively compared outcomes in patients who received T-DXd in the second-line setting versus standard chemotherapy.
"Our study suggests that T-DXd may improve long-term survival when used earlier in treatment, with manageable real-world safety," explains Dr. Shah, Hematology/Oncology Fellow at Roswell Park.
To provide a more accurate assessment of the drug's effects outside of a clinical trial, Dr. Shah and her colleagues analyzed data from 11,112 patients, including 9,135 treated with standard chemotherapy and 1,977 treated with T-DXd. While overall survival was similar at one year, at five years T-DXd showed a clear advantage, with a 58% overall survival rate compared with 49% in the standard chemotherapy group.
"In this study, trastuzumab deruxtecan was associated with improved long-term survival compared with standard chemotherapy, along with a lower risk of death and a manageable safety profile," says Dr. Shah. "These findings suggest it may offer a meaningful benefit for patients with HER2-positive metastatic colorectal cancer, improving outcomes in this aggressive disease."
"While trastuzumab deruxtecan has typically been used in advanced colorectal cancer in later lines of therapy -third line or beyond -this retrospective real-world study shows that patients had improved survival outcomes if T-DXd was used earlier in patients with HER2-positive colorectal cancer. "However, prospective clinical trials are needed to validate these findings. Pulmonary toxicity will also need to be considered in patients who receive T-DXd," adds Kannan Thanikachalam, MD, Assistant Professor of Gastrointestinal Medical Oncology, Department of Medicine, co-senior author of the study.
"Results from this study are strikingly similar to trial data from HER2-positive metastatic breast cancer showing preserved or improved efficacy of trastuzumab deruxtecan when used in earlier lines," says Sheheryar Kabraji, BMBCh, Chief of Breast Medicine and Director of Breast Translational Research at Roswell Park, also co-senior author of the study. "This work is an important example of how clinicians can use real-world data to optimize therapies for an aggressive cancer like HER2-positive colorectal disease. Analyses like this help move the field toward more precise, evidence-based treatment strategies that can ultimately improve patient outcomes."
From the world's first chemotherapy research to the PSA prostate cancer biomarker, Roswell Park Comprehensive Cancer Center generates innovations that shape how cancer is detected, treated and prevented worldwide. The Roswell Park team of 4,000+ makes compassionate, patient-centered cancer care and services accessible across New York State and beyond. Rated "Exceptional" by the National Cancer Institute, Roswell Park, founded in 1898, was one of the first NCI-designated comprehensive cancer centers in the country and remains the only one in Upstate New York. To learn more about Roswell Park Comprehensive Cancer Center and the Roswell Park Care Network, visit www.roswellpark.org, call 1-800-ROSWELL (1-800-767-9355) or email ASKRoswell@RoswellPark.org.
Media Contact
Jane Rose, Media Relations Specialist
716-845-4919; jane.rose@roswellpark.org
***
Original text here: https://www.roswellpark.org/newsroom/202604-aacr-2026-real-world-data-show-targeted-therapy-extends-survival-aggressive-form
University of Michigan Center for Innovation, Related Companies and Olympia Development of Michigan Break Ground on Founders House
NEW YORK, April 18 -- The Related Companies L.P. issued the following news release on April 17, 2026:
* * *
University of Michigan Center for Innovation, Related Companies and Olympia Development of Michigan Break Ground on Founders House
Located on the UMCI Campus at 2205 Cass Avenue, the 313-Unit Residential Building will be Home to Graduate Students and Faculty
*
Detroit - Today, The University of Michigan Center for Innovation (UMCI), Related Companies and Olympia Development of Michigan broke ground on Founders House, the new UMCI residential building for graduate student and faculty
... Show Full Article
NEW YORK, April 18 -- The Related Companies L.P. issued the following news release on April 17, 2026:
* * *
University of Michigan Center for Innovation, Related Companies and Olympia Development of Michigan Break Ground on Founders House
Located on the UMCI Campus at 2205 Cass Avenue, the 313-Unit Residential Building will be Home to Graduate Students and Faculty
*
Detroit - Today, The University of Michigan Center for Innovation (UMCI), Related Companies and Olympia Development of Michigan broke ground on Founders House, the new UMCI residential building for graduate student and facultyhousing. Located at 2205 Cass Avenue, Founders House is part of the Transformational Brownfield Plan (TBP) for The District Detroit, a premier sports and entertainment destination featuring residential, retail, educational and office space in the heart of the city.
Founders House is located adjacent to the UMCI academic building, which is currently under construction and expected to be completed by summer 2027. Designed by Elkus Manfredi Architects with Neumann/Smith Architecture as the Architect of Record, Founders house is expected to achieve LEED Gold. The approximately 235,000-square-foot residential building will rise 13 stories and include 313 residential units, ranging from studios to one-, two- and three-bedroom apartments. UMCI will lease the residential building, which is anticipated to be completed in 2028, for an initial term of 40 years.
"This new 313-unit residential building for the UMCI represents the University of Michigan's strong commitment to attracting and cultivating talent and innovation here in Detroit," said Mayor Mary Sheffield. "Projects like this show what Detroit has to offer on a state, national and global level."
"We're proud to celebrate the groundbreaking of the UMCI residential building. This moment reflects a deeper commitment, one rooted in investing in people, in place and in opportunity," said Scott Shireman, Executive Director, the University of Michigan Center for Innovation in Detroit.
"Detroit has long been a center of opportunity, growth and entrepreneurship and the University of Michigan Center for Innovation will help inspire the next generation of talent," said Related Companies and Olympia Development of Michigan. "Founders House will not only deliver high-quality homes for graduate students and faculty members, but it will also demonstrate what's possible when we come together to invest in the City's future. We are proud to reach this milestone on the UMCI campus - a place for quality jobs, economic opportunity and learning in the heart of The District Detroit."
The University of Michigan Center for Innovation will be a world-class hub for research, education, and entrepreneurship, designed to advance innovation and talent-focused community development and drive job creation and economic growth across the city, region, and state. Located between Cass Avenue and Grand River and bounded by W. Columbia Street to the north and Elizabeth Street to the south, UMCI will, once complete, include a 200,000-square-foot research and education center, a technology incubator, Founders House, and approximately one acre of public green space.
For more information on The University of Michigan Center for Innovation, please visit HERE (https://detroit.umich.edu/umci/).
* * *
About The University of Michigan Center for Innovation
UMCI is designed to be a world-class research, education and entrepreneurship center to advance innovation and talent-focused community development to propel city, regional and statewide job creation and inclusive economic growth by stimulating economic development in Detroit. The center was made possible by a $100 million gift from donor Stephen M. Ross, $100 million from the state of Michigan, a land donation of 2.08 acres at the intersection of Grand River Avenue and West Columbia Street from Olympia Development of Michigan, and other donors.
* * *
About Related Companies
Related Companies is a global real estate and lifestyle company defined by innovation and the most prominent privately-owned real estate firm in the United States. Formed over 50 years ago, Related is one of the largest private owners and preservationists of affordable housing in the U.S. and a fully integrated, highly diversified industry leader with experience in virtually every aspect of development, acquisition, management, finance, marketing, and sales. Headquartered in New York City, Related has offices and major developments in Boston, Chicago, Los Angeles, San Francisco, Texas, Washington, D.C., and London and boasts a team of approximately 4,000 professionals. The company's portfolio of over $70 billion in assets owned or under development includes the 28-acre Hudson Yards neighborhood on Manhattan's West Side, Deutsche Bank Center at Columbus Circle and The 78 in Chicago. Related was named to Fast Company Magazine's list of the 50 Most Innovative Companies in the World. For more information about Related, please visit www.related.com.
* * *
About Olympia Development of Michigan
Olympia Development, an Ilitch company, creates globally recognized, dynamic sports and entertainment destinations through inclusive placemaking, innovative design and construction, and catalytic developments. With billions in development projects, Olympia has a proven track record in residential, commercial, mixed-use, retail, entertainment, sports venues, and institutional developments. As a full-service development group, the company emphasizes strategic planning, community engagement, sustainability, and long-term value creation for our partners and stakeholders. For more information about Olympia Development, please visit www.olympiadevelopmentmi.com.
* * *
Original text here: https://www.related.com/press-releases/2026-04-17/university-michigan-center-innovation-related-companies-and-olympia?_gl=1*1cswwn2*_up*MQ..*_ga*MTQ4MzY5OTY4NS4xNzc2NDg1NDI0*_ga_R55ZFS711N*czE3NzY0ODU0MjMkbzEkZzAkdDE3NzY0ODU0MjMkajYwJGwwJGgw
[Category: BizReal Estate]
News 12 Launches In2, Delivering Award Winning News 12 Original Series Across Crime, Travel, Sports and More
NEW YORK, April 18 -- News 12, a brand of Optimum Communications, issued the following news release on April 17, 2026:
* * *
News 12 Launches in2, Delivering Award Winning News 12 Original Series Across Crime, Travel, Sports and More
Bethpage, NY -- News 12, the preeminent hyperlocal news source across the New York tri-state area, today announced in2, a new destination for News 12 Original Series, is now live. in2 brings viewers a curated collection of critically acclaimed documentaries and series rooted in authenticity, in depth reporting, and powerful storytelling. Viewers will be able to
... Show Full Article
NEW YORK, April 18 -- News 12, a brand of Optimum Communications, issued the following news release on April 17, 2026:
* * *
News 12 Launches in2, Delivering Award Winning News 12 Original Series Across Crime, Travel, Sports and More
Bethpage, NY -- News 12, the preeminent hyperlocal news source across the New York tri-state area, today announced in2, a new destination for News 12 Original Series, is now live. in2 brings viewers a curated collection of critically acclaimed documentaries and series rooted in authenticity, in depth reporting, and powerful storytelling. Viewers will be able tofind in2 on Channel 1 on Optimum in the Northeast and Channel 88 across the rest of the Optimum footprint.
Born out of the award winning journalism of News 12, in2 immerses audiences in compelling stories across true crime, history, travel, wellness, documentaries and sports. Each series is based in fact and designed to create a deep connection with complex characters, iconic locations and meaningful real world stories.
"We're thrilled to bring News 12's award-winning originals to even more viewers with in2," said Audrey Gruber, SVP & GM, News 12. "From chilling real life mysteries and architectural wonders to exclusive access to beloved sports franchises, in2 delivers programming that educates, informs and entertains. Whatever you're in2, you'll find it here."
The network features an expansive library of News 12 Original Series, including content spanning:
* True Crime: suspenseful, analytical storytelling grounded in responsible reporting including the Emmy(R) award winning hit series Crime Files.
* Travel & History: enlightening explorations of regional landmarks and cultural stories, from Down the Shore and The East End to Revealed and Haunted Tri-State.
* Sports: passionate, energetic access to iconic teams and franchises like Inside The Yankees and Inside The Nets.
* Wellness & Documentaries: thoughtful, authentic stories that inspire like beWell and hard-hitting investigations that educate and inform from Turn to Tara to Kane In Your Corner.
* And much more.
With a tone that is authentic, respectful and story driven, in2 reflects the journalistic values that have defined News 12 while offering a fresh, modern viewing experience across platforms. Viewers are invited to discover what they're in2 on Channel 1 on Optimum in the Northeast and Channel 88 across the rest of the Optimum footprint.
Get in2 it.
* * *
Original text here: https://www.optimum.com/about-us/news/articles/news-12-launches-in2-delivering-award-winning-news-12-original-series-across-crime
[Category: BizMedia]
HSF Kramer Secures $17 Million Patent Verdict for Cyandia Against SAP America, SAP SE
NEW YORK, April 18 -- Herbert Smith Freehills Kramer LLP, a law firm, issued the following news on April 17, 2026:
* * *
HSF Kramer secures $17 million patent verdict for Cyandia against SAP America, SAP SE
On April 16, 2026, a jury in the U.S. District Court, Eastern District of Texas, returned a $17 million verdict in favor of Herbert Smith Freehills Kramer client Cyandia Inc. in its patent infringement case against SAP America Inc. and SAP SE (collectively, SAP). The jury found that SAP had violated two of Cyandia's patents covering technologies for managing multiple information forms across
... Show Full Article
NEW YORK, April 18 -- Herbert Smith Freehills Kramer LLP, a law firm, issued the following news on April 17, 2026:
* * *
HSF Kramer secures $17 million patent verdict for Cyandia against SAP America, SAP SE
On April 16, 2026, a jury in the U.S. District Court, Eastern District of Texas, returned a $17 million verdict in favor of Herbert Smith Freehills Kramer client Cyandia Inc. in its patent infringement case against SAP America Inc. and SAP SE (collectively, SAP). The jury found that SAP had violated two of Cyandia's patents covering technologies for managing multiple information forms acrosscomputing devices and that the infringement was willful. The verdict stems from Cyandia's February 2024 suit alleging that SAP willfully infringed some of its patents. SAP's efforts to have one of the patents invalidated by the Patent Trial and Appeal Board (PTAB) were unsuccessful. Two of the patents proceeded to trial, resulting in the jury's verdict for Cyandia.
The HSF Kramer team representing Cyandia was led by Intellectual Property partner Paul J. Andre and included partners Lisa Kobialka, James Hannah and Kristopher B. Kastens; senior associates Aakash Jariwala, and Shreya Ramchandani; and associates Timothy Layden, Dana Anderson, Charles Keller and Violaine Brunet.
* * *
Original text here: https://www.hsfkramer.com/news/2026-04/hsf-kramer-secures-usd-17-million-patent-verdict-for-cyandia-against-sap-america-sap-se
[Category: BizLaw/Legal]
Fisher Phillips Issues Insight: Alabama Enacts Sweeping Consumer Privacy Law - 7 Steps Your Business Should Consider to Prepare
ATLANTA, Georgia, April 18 -- Fisher Phillips, a law firm, issued the following insight on April 17, 2026:
* * *
Alabama Enacts Sweeping Consumer Privacy Law: 7 Steps Your Business Should Consider to Prepare
Alabama just joined 20 others states by enacting a comprehensive consumer privacy law, and businesses must get ready to comply with sweeping new obligations that will kick in next year. The state's new Alabama Personal Data Protection Act (APDPA), signed into effect yesterday by Governor Ivey, establishes a broad privacy framework for how businesses collect and sell consumers' personal data.
... Show Full Article
ATLANTA, Georgia, April 18 -- Fisher Phillips, a law firm, issued the following insight on April 17, 2026:
* * *
Alabama Enacts Sweeping Consumer Privacy Law: 7 Steps Your Business Should Consider to Prepare
Alabama just joined 20 others states by enacting a comprehensive consumer privacy law, and businesses must get ready to comply with sweeping new obligations that will kick in next year. The state's new Alabama Personal Data Protection Act (APDPA), signed into effect yesterday by Governor Ivey, establishes a broad privacy framework for how businesses collect and sell consumers' personal data.We'll explain key aspects of the new law and offer seven steps you can take now to prepare.
Table of Contents
* Overview
* Scope and Applicability
- Covered Consumers
- Covered Data
- Covered Businesses
- Controllers vs. Processors
* Controller Duties
- Complying With Consumer Requests
- Data Minimization, Consumer Privacy Notice, and More
* Processor Duties
* Enforcement
* 7 Steps Your Business Should Consider Taking Now
* Conclusion
Overview
Governor Kay Ivey just signed a bill (HB 351) into law that establishes the Alabama Personal Data Protection Act (APDPA). The new law, which takes effect May 1, 2027, establishes:
* data privacy rights for consumers;
* duties for "controllers" (see "Controllers vs. Processors" below);
* duties for "processors" (see "Controllers vs. Processors" below); and
* enforcement measures.
While the law imposes extensive obligations on covered businesses, it also includes many broad exemptions and carve-outs. We'll cover some of the highlights below, but you should work with counsel to understand whether and how the APDPA applies to your business in various specific data processing situations.
Scope and Applicability
Covered Consumers
The APDPA aims to protect consumers who are residents of Alabama. Importantly, however, it does not cover individuals acting in a commercial or employment context or as an employee, owner, director, officer, or contractor.
The APDPA's employment-data exception is consistent with all other state consumer privacy laws, except for the California Consumer Privacy Act (CCPA), which broadly defines "consumer" to include job applicants, current and former employees, and more.
Covered Data
The APDPA protects consumers' personal data, which means any information that is linked or reasonably linkable to an identified or an individual who can be readily identified, directly or indirectly.
However, "personal data" does not include deidentified data (so long as the controller possessing the data complies with certain conditions) or publicly available information. In addition, the new state law specifies various types of data that are not covered by the APDPA, including, for example:
* many types of federally regulated data, such as protected health information under HIPAA or consumer reporting data covered by the Fair Credit Reporting Act;
* employment and HR data, such as information related to job applicants, current employees, contractors, or agents, as well as certain emergency contact and benefits administration data; and
* data or information collected or processed to comply with state law.
Covered Businesses
The APDPA applies to businesses that:
* operate in Alabama or produce products or services that target residents of the state; and
* control or process the personal data of more than 25,000 consumers or derive more than 25% of gross revenue from the "sale of personal data" (see below for more details).
Sale of Personal Data. Under the APDPA, a sale of personal data occurs (subject to any applicable exclusions) when a controller sells a consumer's personal data to a third party (without restricting how the third party may use that data in the future) in exchange for monetary or "other valuable" consideration that materially benefits the controller. While some states define the sale of data strictly to mean disclosures in exchange for monetary consideration, Alabama joins the batch of states that expand the definition to include disclosures in exchange for other things of real value, not just monetary consideration. But unlike other states, Alabama limits this "other valuable" category to only consideration that materially benefits the controller. In the context of website cookies, this definition may implicate the sharing of data through certain cookies unless the following exception applies. The APDPA includes some significant carveouts from what would be considered selling of data (in addition to other standard types of exclusions included in most state consumer privacy laws) for certain types of data disclosures or transfers. For example, under the Alabama law, the disclosure or transfer of personal data to a third party for the purposes of providing analytics services or providing marketing services solely to the controller will not be treated as sales of personal data.
Notably, these thresholds make it easier for a business to be covered compared to the thresholds under other states' privacy laws. However, the new law provides various important exemptions, many of which go far beyond the exemptions available under other state laws of this kind. For example, the following entities will not be required to comply with the APDPA:
* Political subdivisions of the state, or any board, authority, district, or public corporation.
* Two-year or four-year institutions of higher education, as well as their affiliates.
* National registered securities associations.
* Certain federally regulated financial institutions and their affiliates.
* HIPAA covered entities or business associates.
* Businesses with fewer than 500 employees, so long as the business does not engage in the sale of personal data.
* Nonprofit entities with fewer than 100 employees, so long as the entity does not engage in the sale of personal data.
* Certain regulated industries.
* Trade associations explicitly authorized to receive certain documents or evidence from state insurance regulators.
* Certain political action committees, political parties, or principal campaign committees, and political organizations, as well as businesses that primarily sell data to them.
* Electric providers subject to national reliability standards.
Controllers vs. Processors
If a business is covered by the APDPA, it must meet certain compliance requirements, which vary depending on whether the business is a "controller" or a "processor." Here's what these terms mean:
* A controller is an "individual or legal entity that, alone or jointly with others, determines the purposes and means of processing personal data."
* A processor is an "individual or legal entity that processes personal data on behalf of a controller."
Whether a person is acting as a controller or processor with respect to a specific processing of data is a fact-based determination that depends on criteria laid out under the APDPA.
Controller Duties
Complying With Consumer Requests
A controller must comply with a consumer's authenticated request to invoke any of their rights under the APDPA, including requests for the controller to:
* Confirm whether the controller (or a processor or third party acting on its behalf) is processing the consumer's personal data and accessing any of their personal data under its control - unless confirmation or access would require the controller to reveal a trade secret.
* Correct inaccuracies in the consumer's personal data, considering the nature of it and the purposes for processing it.
* Delete the consumer's personal data.
* Provide a copy of the consumer's personal data (as previously provided by the consumer to the controller) in a format that meets certain conditions - unless providing the data would require the controller to reveal a trade secret.
* Allow the consumer to opt out of the processing of their personal data for the purpose of targeted advertising, sale of the data, or profiling in connection with solely automated significant decisions concerning them.
If a consumer is a child under age 13, these consumer rights may be exercised by their parent or legal guardian (and the same is true for guardian-consumer or conservator-consumer relationships, regardless of age).
In addition, controllers will be required to establish a secure and reliable method for consumers to exercise these rights and to follow certain procedures when handling consumers' requests, including, for example:
* responding to the consumer within 45 days after receiving their request (extensions are available under specific conditions) and, if applicable, provide justification for declining the request; and
* providing information in response to an authenticated request free of charge once per consumer during any 12-month period (subject to limited exceptions that allow the controller to charge the consumer a reasonable fee).
Other Controller Duties: Data Minimization, Consumer Privacy Notice, and More
The APDPA will impose many other compliance requirements on controllers. As just a few examples, controllers will be:
* limited to collecting personal data that is "adequate, relevant, and necessary" in relation to the purpose for processing it;
* required to establish and maintain "reasonably administrative, technical, and physical data security practices to protect the confidentiality, integrity, and accessibility of personal data appropriate to the volume and nature of the personal data at issue";
* prohibited from, among other things, processing personal data for purposes that are not compatible with the disclosed purposes for processing it or processing a consumer's "sensitive data" without obtaining their consent (note: personal data of a known child under age 13 must be processed in accordance with the federal Children's Online Privacy Protection Act);
* required to provide consumers with a privacy notice that meets certain criteria; and
* required to handle deidentified data in accordance with specific rules.
Notably, however, the APDPA stops short of imposing several significant requirements that are included in consumer privacy laws in many other states. For example, the APDPA does not require controllers to conduct data protection impact assessments or implement universal opt-out preference signals.
Processor Duties
Processors will be required to adhere to the controller's instructions and take measures to assist the controller in complying with its obligations under the APDPA. The law also establishes requirements for contracts between controllers and processors.
Enforcement
Alabama's attorney general will have the power to enforce the APDPA and will be required to issue a notice of violation to the controller before initiating any action against it. The controller will then have 45 days to correct the alleged violation and notify the attorney general of the correction - if it fails to do so, the AG may bring an action in court, and, if the court finds against the controller, it may assess a civil penalty of up to $15,000 per violation.
7 Steps Your Business Should Consider Taking Now
If your business is covered by the APDPA, here are six steps you should consider taking now ahead of the law's May 1, 2027, effective date:
* Evaluate your organization's current data collection and privacy procedures.
* Review existing privacy notices and policies, including those drafted for compliance with the laws of other jurisdictions that have passed similar consumer privacy legislation.
* Implement systems to respond to authenticated consumer requests to invoke their rights under the APDPA.
* Consider engaging in a data mapping exercise, if your business has not done so recently, to identify consumer data your organization has collected and where that data resides.
* Identify third parties with whom your business shares consumer data and any existing data processing agreements with those entities.
* Assess your collection of data concerning minors (if any).
* Stay tuned for updates and work with data privacy counsel to evaluate your business's readiness for compliance with the APDPA.
Conclusion
As consumers demand more transparency about who receives their data and what it's used for, and without progress on a federal data privacy scheme, we expect more proposed legislation at the state level, as 20 other states have already enacted similar laws - including, most recently, the Oklahoma Consumer Data Privacy Act enacted last month.
Fisher Phillips will continue to monitor developments in this area and provide updates as warranted, so make sure you are subscribed to Fisher Phillips' Insight System to get the most up-to-date information direct to your inbox. You can also visit FP's U.S. Consumer Privacy Hub for additional resources to help you navigate this area. If you have questions, please contact your Fisher Phillips attorney, the authors of this Insight, any member of our Privacy and Cyber team or any attorney in our Birmingham office.
* * *
Related People
Ree Harper
Partner
rharper@fisherphillips.com
205.963.5403
* * *
Raymond W. Perez
Of Counsel
rwperez@fisherphillips.com
205.963.5400
* * *
Original text here: https://www.fisherphillips.com/en/insights/insights/alabama-enacts-sweeping-consumer-privacy-law
[Category: BizLaw/Legal]
Buffalo Sabres and Delaware North Release 2026 NHL Playoff Food and Beverage Highlights
BUFFALO, New York, April 18 -- Delaware North issued the following news release:
* * *
Buffalo Sabres and Delaware North release 2026 NHL Playoff food and beverage highlights
As the NHL playoffs ignite excitement across Buffalo, the Sabres are ready to welcome fans to KeyBank Center for the first thrilling postseason in 14 years. As the hospitality leader at the arena, Delaware North Sportservice has crafted a lineup of innovative food and beverage options, ensuring that every game is celebrated with signature flavors and top-notch service for Sabres fans.
Concessions Menu Items
* Let's Go
... Show Full Article
BUFFALO, New York, April 18 -- Delaware North issued the following news release:
* * *
Buffalo Sabres and Delaware North release 2026 NHL Playoff food and beverage highlights
As the NHL playoffs ignite excitement across Buffalo, the Sabres are ready to welcome fans to KeyBank Center for the first thrilling postseason in 14 years. As the hospitality leader at the arena, Delaware North Sportservice has crafted a lineup of innovative food and beverage options, ensuring that every game is celebrated with signature flavors and top-notch service for Sabres fans.
Concessions Menu Items
* Let's GoBuffalo Wings & Pizza Logs: Served in a souvenir Sabres ice rink tray! 10 Buffalo-style chicken wings, 8 pizza logs, served with blue cheese, marinara and celery sticks. Available at 100 level Blue Line Fryer.
* Return of the Dominator: Four burger patties, brisket, bacon, house-made jalapeno peppers, boom-boom sauce, American cheese and ancho BBQ sauce, served between two pepperjack grilled cheese sandwiches. Available at 100 level Grill stand.
* Buffalo Sabres Are A Wagon: Chicken tenders and French fries served in a custom Sabres wagon box. Available at 100 & 300 level Coca-Cola stands.
* Sabres Steakhouse Stack: 6 oz. beef filet, shoestring fries, raclette cheese, caramelized onion aioli, on a Sabres-branded brioche bun. Available at 100 level Coca-Cola stand.
* Pretzel Bites: Salted soft pretzel bites, served in a souvenir helmet. Available at Power Play Pretzel.
* Hot Dog of the Game: Poutine Dog: Hot dog, brisket, bacon, French fries and cheddar cheese curds. Available at 100 & 300 level Top Dog.
* La Nova Stinger Pizza: Chicken fingers, top round steak, hot sauce and blue cheese dressing. Available at all La Nova locations.
* The Tommer Bomber: House-made meatballs, melted mozzarella, garlic bread and potato chips, served in a custom Sabres wagon box. Available at La Nova stand near section 116.
* 2 Foot Steak & Cheese Nachos: Sliced beef, white queso, lettuce, tomato, onion and zesty aioli on top of tortilla chips. Available at Party Nacho.
Desserts
* Sponge Candy Crunch Fried Dough: Fried dough, hot fudge, warm caramel, crushed sponge candy. Available at Let's Dough Buffalo stands.
* Timmy Shake: Perry's vanilla ice cream milkshake with Tim Hortons Timbits. Available at Perry's Ice Cream stand near section 106 and Let's Dough stands.
* Cinnamon Sugar Pretzel Bites: Cinnamon sugar pretzel bites with cream cheese icing, served in a souvenir helmet. Available at Power Play Pretzel.
* Dubai Chocolate Pretzel Braid: Braided pretzel topped with pistachio cream, Kataifi and chocolate drizzle. Available at Power Play Pretzel.
Club Concessions
* Pulled Pork Eggroll: Pulled pork, bread and butter pickles, Carolina gold BBQ sauce. Available at the Fryer's Club stand.
* Chicken Wing Loaded Tots: Shredded Buffalo chicken, blue cheese crumble, celery and carrots on top of tater tots. Available at the Fryer's Club stand.
* Juicy Lucy Burger: 6 oz. burger stuffed with American cheese, bread and butter pickles and fancy sauce. Available at the Corner Market stand.
* Hot Dog of the Game: Poutine Dog: Hot dog topped with brisket, bacon, fries and cheddar curds. Available at the Corner Market stand.
* General Tso's Chicken Sandwich: Chicken sandwich topped with sesame slaw and scallions, served on a sesame seed bun. Available at the Fryer's Club stand.
Suites will have the option of several celebration packages.
* * *
Original text here: https://media.delawarenorth.com/buffalo-sabres-and-delaware-north-release-2026-nhl-playoff-food-and-beverage-highlights/
[Category: BizTravel]
BMJ Group: Buprenorphine is a Safe Treatment for Opioid Addiction in Pregnancy
LONDON, England, April 18 (TNSjou) -- BMJ Group issued the following news release about The BMJ on April 16, 2026:
* * *
Buprenorphine is a safe treatment for opioid addiction in pregnancy
Buprenorphine showed a similar to slightly lower risk of developmental disorders in children compared with methadone, researchers say (https://www.bmj.com/content/393/bmj-2025-087321)
*
Children born to mothers who used buprenorphine for opioid addiction during pregnancy do not have a greater risk of neurodevelopmental disorders, such as ADHD and autism, compared with children whose mothers took methadone,
... Show Full Article
LONDON, England, April 18 (TNSjou) -- BMJ Group issued the following news release about The BMJ on April 16, 2026:
* * *
Buprenorphine is a safe treatment for opioid addiction in pregnancy
Buprenorphine showed a similar to slightly lower risk of developmental disorders in children compared with methadone, researchers say (https://www.bmj.com/content/393/bmj-2025-087321)
*
Children born to mothers who used buprenorphine for opioid addiction during pregnancy do not have a greater risk of neurodevelopmental disorders, such as ADHD and autism, compared with children whose mothers took methadone,finds a large US study published by The BMJ today.
The researchers say these findings "further support buprenorphine as a safe treatment option for opioid use disorder during pregnancy."
Buprenorphine and methadone are recommended for the treatment of opioid use disorder during pregnancy. Previous research has shown that buprenorphine is associated with a lower risk of serious health complications for newborns compared with methadone, but evidence on long term safety is lacking.
To address this gap, researchers used Medicaid health insurance data for over 2.5 million live births from 2000 to 2018 to compare the risk of neurodevelopmental disorders in 12,635 children exposed to buprenorphine with 5,390 children exposed to methadone before birth (prenatally).
The children were tracked up to age 8 for conditions including autism, ADHD, speech or language disorder, behavioural disorder, and intellectual disability.
The researchers accounted for a range of potentially influential factors including mother's age, ethnicity, tobacco and alcohol use, chronic pain, mental health conditions, and use of other medications and healthcare.
After adjusting for these variables, children with prenatal exposure to buprenorphine had a slightly lower (19%) risk of any neurodevelopmental disorder by age 8 compared with those exposed to methadone.
Prenatal exposure to buprenorphine was also associated with a lower risk of specific neurodevelopmental disorders compared with methadone including ADHD (11% lower risk), speech or language disorder (16% lower risk), and autism (26% lower risk).
For women who were already using buprenorphine or methadone before pregnancy (prevalent use), prenatal exposure to buprenorphine was linked to a 38% lower risk of any neurodevelopmental disorder compared with methadone exposure.
However, this association was not observed among women who initiated treatment during pregnancy (new use), a finding the authors suggest requires further study.
Additional analyses to further account for bias also suggested that prenatal buprenorphine exposure does not increase the risk of long term adverse neurodevelopmental outcomes compared with methadone.
This is an observational study, so no firm conclusions can be drawn about cause and effect and the researchers acknowledge some limitations. But they say their use of a large representative health insurance database and extensive sensitivity analyses to examine different sources of bias suggest the findings are robust.
As such, they conclude: "The findings of this study suggest no increased risk of long term adverse neurodevelopmental outcomes among children with prenatal exposure to buprenorphine versus methadone, further supporting buprenorphine as a safe treatment option for opioid use disorder during pregnancy."
These findings are reassuring and should increase confidence in buprenorphine as an option during pregnancy, say Australian researchers in a linked editorial.
However, they stress methadone's importance for those with higher opioid tolerance or more complex needs and the need to address stigma, fragmented services, and structural inequities that hinder care for people with opioid use disorder.
Further research is also needed on other outcomes and new formulations, such as long-acting injectable buprenorphine (currently unstudied in pregnancy) and to ensure that clinical recommendations remain evidence-based and responsive to evolving medication options for opioid use disorder, they conclude.
* * *
Notes for editors
Research: Prenatal exposure to buprenorphine or methadone and adverse neurodevelopmental outcomes: population based cohort study doi: 10.1136/bmj-2025-087321
Editorial: Treatments for opioid use disorder during pregnancy doi: 10.1136/bmj.s593
External funding: National Institute on Drug Abuse and National Institutes of Health
Link to Academy of Medical Sciences press release labelling system: http://press.psprings.co.uk/AMSlabels.pdf
Externally peer reviewed? Yes (research); No (linked editorial)
Evidence type: Observational
Subjects: Children
* * *
Original text here: https://bmjgroup.com/buprenorphine-is-a-safe-treatment-for-opioid-addiction-in-pregnancy/
[Category: BizMedia]
